Dermata Therapeutics falls 13.17% pre-market without new news
Alpha Vantage · Kalkine · · AI-summarised by FinFlash
Dermata Therapeutics (NASDAQ:DRMA) fell 13.17% pre-market to USD 0.7595, with no new company-specific announcements. The drop partly reverses a 37.19% gain on October 15 that followed positive topline results from an open-label cosmetic study of its Tome Foundational Treatment. Investors are watching for third-quarter results and any financing or listing notices, given recurring losses and the company's cash position.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.